-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Excessive alcohol consumption is the most common cause of chronic liver disease (CLD), and alcohol-related liver disease accounts for 5.
1% of the global disease burden
.
Long-term drinking can cause liver steatosis, 10-35% of cases will progress to fibrosis, and 10-20% of cases will progress to cirrhosis
Excessive alcohol consumption is the most common cause of chronic liver disease (CLD), and alcohol-related liver disease accounts for 5.
This study is an observational cohort study.
A total of 786 patients with chronic liver disease due to alcohol (n = 81) and non-alcoholic causes (n = 705) were evaluated
.
There are prognostic data for 64 alcoholic patients, and the average duration of the disease is 6.
The results of this study show that ELF determines cirrhosis and moderate fibrosis of alcohol-related liver disease independently of transaminase levels.
The areas under the receiver operating characteristic curve are (AUC): 0.
895 (95% CI 0.
823–0.
968) and 0.
923 (95% CI 0.
866–0.
981)
.
The Obuchowski method was used to evaluate the overall performance of ELF: alcohol = 0.
This study confirmed that ELF can accurately stage liver fibrosis independently of the elevation of transaminase, which is an inflammation marker, and has superior prognostic performance in biopsy of alcohol-related liver disease
.
.
Original source:
Declan Connoley.
The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.
Leave a message here
